Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 8/20 | 0.73 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.49 |
| ▸ | PTGES | O14684 | 2/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.45 |
| ▸ | GCGR | P47871 | 2/20 | 0.44 |
| ▸ | GIPR | P48546 | 2/20 | 0.44 |
| ▸ | GLP1R | P43220 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1239707 | 1.00 | SERPINE1 (0.73) | SERPINE1NR1H4PTGESALOX5GCGR | |
| SCHEMBL1242155 | 0.97 | SERPINE1 (0.78) | SERPINE1NR1H4PTGESALOX5GCGR | |
| SCHEMBL12952821 | 0.97 | SERPINE1 (0.71) | SERPINE1NR1H4GCGRGIPRGLP1R | |
| SCHEMBL1239985 | 0.95 | SERPINE1 (0.68) | SERPINE1NR1H4GCGRGIPRGLP1R | |
| SCHEMBL1239562 | 0.92 | SERPINE1 (0.64) | SERPINE1NR1H4GCGRGIPRGLP1R | |
| SCHEMBL1241514 | 0.91 | SERPINE1 (0.63) | SERPINE1NR1H4GCGRGIPRGLP1R | |
| SCHEMBL1242244 | 0.91 | SERPINE1 (0.63) | SERPINE1NR1H4GCGRGIPRGLP1R | |
| SCHEMBL13581248 | 0.90 | SERPINE1 (0.61) | SERPINE1NR1H4GCGRGIPRGLP1R | |
| SCHEMBL1241388 | 0.90 | SERPINE1 (0.61) | SERPINE1NR1H4GCGRGIPRGLP1R | |
| SCHEMBL1242234 | 0.90 | SERPINE1 (0.63) | SERPINE1NR1H4GCGRGIPRGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633245-B2 | PAI-1 inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-8633245-B2 | PAI-1 inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-7884234-B2 | N-[4-(tert-butyl)benzyl]-N-[4 -(trifluoromethoxy)biphenyl-3-yl]oxamic Acid; Inhibitors of plasminogen activator inhibitor-1 (PAI-1); thrombogenesis, fibrogenesis, accumulation of visceral fat, cell proliferation, angiogenesis | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2011-02-08 | — | — | US | disclosed |
| US-7884234-B2 | N-[4-(tert-butyl)benzyl]-N-[4 -(trifluoromethoxy)biphenyl-3-yl]oxamic Acid; Inhibitors of plasminogen activator inhibitor-1 (PAI-1); thrombogenesis, fibrogenesis, accumulation of visceral fat, cell proliferation, angiogenesis | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2011-02-08 | — | — | US | disclosed |
| US-7884234-B2 | N-[4-(tert-butyl)benzyl]-N-[4 -(trifluoromethoxy)biphenyl-3-yl]oxamic Acid; Inhibitors of plasminogen activator inhibitor-1 (PAI-1); thrombogenesis, fibrogenesis, accumulation of visceral fat, cell proliferation, angiogenesis | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2011-02-08 | — | — | US | disclosed |
| EP-2272817-A1 | PAI-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20090312315-A1 | PAI-1 INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312315-A1 | PAI-1 INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-17 | — | — | US | disclosed |
| WO-2009125606-A1 | PAI-1 INHIBITOR | 株式会社医薬分子設計研究所 (JP) | 2009-10-15 | — | — | WO | disclosed |
| US-20090215899-A9 | N-Phenyloxamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-08-27 | — | — | US | disclosed |
| US-20090215899-A9 | N-Phenyloxamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-08-27 | — | — | US | disclosed |
| US-20090215899-A9 | N-Phenyloxamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-08-27 | — | — | US | disclosed |
| EP-2072498-A1 | N-PHENYLOXAMIDIC ACID DERIVATIVE | Institute of Medicinal Molecular Design, Inc. (JP) | 2009-06-24 | — | — | EP | disclosed |
| US-20080249175-A1 | N-Phenyloxamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-10-09 | — | — | US | disclosed |
| US-20080249175-A1 | N-Phenyloxamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-10-09 | — | — | US | disclosed |
| US-20080249175-A1 | N-Phenyloxamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249175-A1 | N-Phenyloxamide derivatives | SERPINE1, SERPINH1, F12 | SERPINE1 1/4885NR1H4 4184/4885PTGES 465/4885 |
| US-20090215899-A9 | N-Phenyloxamide derivatives | SERPINE1, SERPINH1, F12 | SERPINE1 1/4885NR1H4 4184/4885PTGES 465/4885 |
| US-20090312315-A1 | PAI-1 INHIBITOR | SERPINC1, SERPINE1, SERPINH1 | SERPINE1 2/4885NR1H4 2901/4885PTGES 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.